The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

Not intended for UK audiences Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2Affecting up to 100,000 people in ...

The prevalence of interstitial lung disease (ILD) across connective tissue disorders (CTDs) and its persistent standing as a leading cause of death in patients with CTDs challenge rheumatologists to ...

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...

Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments ...

The FDA has approved YUTREPIA™ (treprostinil) inhalation powder, developed by Liquidia Corporation, as a treatment option for adults with pulmonary arterial hypertension (PAH) and pulmonary ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

Please provide your email address to receive an email when new articles are posted on . Proton pump inhibitors with histamine 2 receptor antagonists reduced all-cause mortality in patients with ...

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...